Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes

Review (26 RCTs) found that while intravenous TNFs may provide some improvements in patient-reported outcomes relative to several other targeted synthetic DMARDs and biologic DMARDs, differences between classes of therapies across outcomes were small.

SPS commentary:

Studies evaluated inhibitors of the following treatment classes: cytotoxic T-lymphocyte-associated antigen 4 (abatacept), IL-12/23 (ustekinumab), IL-17A (ixekizumab, secukinumab), IL-23 (guselkumab), Janus kinase (tofacitinib), subcutaneous TNF (adalimumab, certolizumab, etanercept, golimumab), intravenous TNF (golimumab, infliximab) and phosphodiesterase-4 (apremilast). The IL-17 receptor A inhibitor brodalumab and JAK inhibitor upadacitinib were not approved at the time of the search (October 2018 to January 2020).

BMJ Open